Skip to content
DraconiticResearch
Search Sources API
197,693 studies31 sourcesUpdated 14 min ago
Peer-reviewedCC BY 4.0Frontiers in Endocrinology

Personalised acromegaly treatment: implementing precision medicine in the Gulf States

  • Tarik Elhadd1
  • Khaled Aldahmani2,3
  • Mussa Almalki4,5
  • Aisha Ekhzaimy6
  • Raya Almazrouei2,3
  • Zainab Dabbous1
  • Zaina Rohani1
  • Ali Alzahrani7,8
8 affiliations
  1. 1Qatar Metabolic Institute, Department of Medicine, Hamad Medical Corporation
  2. 2Division of Endocrinology, Tawam Hospital & Sheikh Tahnoon Bin Mohammed Medical City (STMC)
  3. 3Department of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University
  4. 4Obesity, Endocrine, and Metabolism Center, King Fahad Medical City, Second Health Cluster
  5. 5College of Medicine, Alfaisal University
  6. 6Endocrinology & Diabetes Unit, Department of Medicine, College of Medicine and King Saud University Medical City, King Saud University
  7. 7Department of Medicine, King Faisal Specialist Hospital and Research Center
  8. 8Molecular Endocrine Section, Research and Innovation, King Faisal Specialist Hospital and Research Center
Read full textPDFDOICite

Abstract

Acromegaly management in the Gulf region is complicated by a high burden of metabolic comorbidity, frequent presentation with macroadenomas and suboptimal biochemical control in available regional cohorts. Conventional first-generation somatostatin receptor ligands achieve biochemical control in only 30-40% of patients, rates lower than those observed in European cohorts, necessitating precision medicine strategies. MRI signal and tumour granulation patterns represent the most widely available biomarkers in Gulf healthcare systems and enable precise treatment selection. These biomarkers may help predict poor first-generation therapy response while identifying patients who may benefit from pasireotide, an efficacious second-generation somatostatin receptor ligand with multi-receptor binding capacity. Implementation of biomarker-guided therapy in Gulf healthcare systems can optimize therapeutic outcomes while addressing regional challenges of delayed diagnosis and advanced disease presentation. Regional challenges specific to Gulf healthcare systems are identified and a practical biomarker-guided algorithm tailored for the GCC region is proposed to optimise treatment selection using readily available diagnostic tools. This approach is more appropriate for Gulf populations who present with more advanced disease characteristics that may benefit from precision-guided first-line treatment selection, representing a paradigm shift away from current guideline recommendations toward truly personalised medicine. This evolution from empirical to precision medicine represents a potential advancement for improving acromegaly management where complex metabolic phenotypes demand sophisticated treatment strategies.

Related

  1. Case Report: Multimodal treatment of pediatric H3G34-mutant diffuse hemispheric glioma: a safety and feasibility case report combining precision medicine and tumor treating fields with conventional care
    Toon Van Genechten, Alexander Claviez, Sebastian Oberbeck +11
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyFrontiersCrossrefDOAJ
  2. Pediatric MASLD in the precision medicine era: advances in diagnosis, prevention, and treatment
    Anastasia Ntikoudi, Anastasia Papachristou, Eugenia Vlachou
    Frontiers in medicinePeer-reviewedCC BYFull textEpidemiology & public healthEurope PMCEurope PMCPMC
  3. The role of personalised medicine in treating high-risk neuroblastoma in paediatric patients.
    Daniele Ammeti, Debora Curci, Martina Franzin +3
    Oncology reviewsPeer-reviewedCC BYFull textNeurologyEurope PMC
  4. Geriatric respiratory medicine 2026: from artificial intelligence to personalised management of the multimorbid patient.
    Claudio Sorino, Paolo Cameli, Giorgio Walter Canonica +18
    European respiratory review : an official journal of the European Respiratory SocietyPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  5. Polygenic prediction of treatment response for precision medicine is vulnerable to collider bias
    M. J. Tudball, E. T. Cirulli, M. V. Holmes +2
    medRxivPreprintCC BYFull textHuman geneticsmedRxiv

Cite

BibTeXRIS
BibTeX
@article{elhadd2026personalised,
  title = {{Personalised acromegaly treatment: implementing precision medicine in the Gulf States}},
  author = {Tarik Elhadd and Khaled Aldahmani and Mussa Almalki and Aisha Ekhzaimy and Raya Almazrouei and Zainab Dabbous and Zaina Rohani and Ali Alzahrani},
  journal = {Frontiers in Endocrinology},
  year = {2026},
  month = oct,
  doi = {10.3389/fendo.2026.1951420},
  url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1951420/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Personalised acromegaly treatment: implementing precision medicine in the Gulf States
AU  - Tarik Elhadd
AU  - Khaled Aldahmani
AU  - Mussa Almalki
AU  - Aisha Ekhzaimy
AU  - Raya Almazrouei
AU  - Zainab Dabbous
AU  - Zaina Rohani
AU  - Ali Alzahrani
PY  - 2026
DA  - 2026/10/13
JO  - Frontiers in Endocrinology
DO  - 10.3389/fendo.2026.1951420
UR  - https://www.frontiersin.org/articles/10.3389/fendo.2026.1951420/full
AB  - Acromegaly management in the Gulf region is complicated by a high burden of metabolic comorbidity, frequent presentation with macroadenomas and suboptimal biochemical control in available regional cohorts. Conventional first-generation somatostatin receptor ligands achieve biochemical control in only 30-40% of patients, rates lower than those observed in European cohorts, necessitating precision medicine strategies. MRI signal and tumour granulation patterns represent the most widely available biomarkers in Gulf healthcare systems and enable precise treatment selection. These biomarkers may help predict poor first-generation therapy response while identifying patients who may benefit from pasireotide, an efficacious second-generation somatostatin receptor ligand with multi-receptor binding capacity. Implementation of biomarker-guided therapy in Gulf healthcare systems can optimize therapeutic outcomes while addressing regional challenges of delayed diagnosis and advanced disease presentation. Regional challenges specific to Gulf healthcare systems are identified and a practical biomarker-guided algorithm tailored for the GCC region is proposed to optimise treatment selection using readily available diagnostic tools. This approach is more appropriate for Gulf populations who present with more advanced disease characteristics that may benefit from precision-guided first-line treatment selection, representing a paradigm shift away from current guideline recommendations toward truly personalised medicine. This evolution from empirical to precision medicine represents a potential advancement for improving acromegaly management where complex metabolic phenotypes demand sophisticated treatment strategies.
SN  - 1664-2392
ER  -